Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Eckert & Ziegler SE's share price for the quarter that ended in Mar. 2026 was €14.62. Eckert & Ziegler SE's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 62.6 Mil. Therefore, Eckert & Ziegler SE's market cap for the quarter that ended in Mar. 2026 was €914.9 Mil.
Eckert & Ziegler SE's quarterly market cap
declined
from Sep. 2025 (€1,115.1 Mil) to Dec. 2025 (€954.9 Mil) and
declined
from Dec. 2025 (€954.9 Mil) to Mar. 2026 (€914.9 Mil).
Eckert & Ziegler SE's annual market cap
increased
from Dec. 2023 (€775.7 Mil) to Dec. 2024 (€927.6 Mil) and
increased
from Dec. 2024 (€927.6 Mil) to Dec. 2025 (€954.9 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Eckert & Ziegler SE's Enterprise Value for Today is €876.2 Mil.
Eckert & Ziegler SE (XTER:EUZ) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Eckert & Ziegler SE Market Cap Related Terms
Eckert & Ziegler SE Market Cap Historical Data
* Premium members only.
The historical data trend for Eckert & Ziegler SE's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Eckert & Ziegler SE's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's Market Cap distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Eckert & Ziegler SE's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eckert & Ziegler SE (XTER:EUZ) has a Market Cap of €955.5 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eckert & Ziegler SE and its competitors. According to the industry distribution chart, Eckert & Ziegler SE ranks #168 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 19.4%.
Is Eckert & Ziegler SE's Market Cap too high?
Eckert & Ziegler SE's current Market Cap is €955.5 Mil. Based on the distribution chart, Eckert & Ziegler SE ranks #168 out of 867 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Eckert & Ziegler SE ranks #168 out of 867 companies for Market Cap. This places Eckert & Ziegler SE in the top 19% of its industry — outperforming the majority of peers. The industry median Market Cap is 120.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.18, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Eckert & Ziegler SE and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eckert & Ziegler SE's current Market Cap is €955.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (XTER:EUZ) is currently considered Fairly Valued. The stock's GF Value™ is €16.25, compared to a current price of €15.27 — trading 6% below its estimated fair value. The current Market Cap is €955.5 Mil. Eckert & Ziegler SE's overall GF Score™ is 98/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Eckert & Ziegler SE (XTER:EUZ), the current Market Cap is €955.5 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (XTER:EUZ) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.27 is trading 6% below its estimated GF Value™ of €16.25.
GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.
Key valuation signals for XTER:EUZ:
Market Cap: €955.5 Mil
GF Value™: €16.25 vs. price of €15.27 (6% below fair value)
No single metric tells the full story. See the XTER:EUZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for XTER:EUZ
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:EUZ has been successfully added to your 
